Eribulin-induced Interstitial Pneumonia : A Case Series and Retrospective Cohort Study
Eribulin is a chemotherapeutic agent used for advanced breast cancer, but there are some reports of eribulin-induced lung injuries. Three of our patients experienced eribulin-related lung injuries. Radiology revealed organizing pneumonia in two cases and diffuse ground-glass shadows indicative of hypersensitivity pneumonitis in the third. A retrospective survey of patients treated with eribulin at our hospital identified no other cases of eribulin-induced lung injuries. Overall, drug-related lung injuries occurred in 2.8% of our eribulin-treated patients, which is similar to the rates reported for other anticancer drugs. The findings from these three cases provide guidance for the safe use of eribulin.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:59 |
|---|---|
| Enthalten in: |
Internal medicine (Tokyo, Japan) - 59(2020), 4 vom: 15. Feb., Seite 563-567 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Murakami, Manabu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antineoplastic Agents |
|---|
| Anmerkungen: |
Date Completed 02.09.2020 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2169/internalmedicine.2779-19 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM301952361 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM301952361 | ||
| 003 | DE-627 | ||
| 005 | 20231225105707.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2169/internalmedicine.2779-19 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1006.xml |
| 035 | |a (DE-627)NLM301952361 | ||
| 035 | |a (NLM)31588076 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Murakami, Manabu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Eribulin-induced Interstitial Pneumonia |b A Case Series and Retrospective Cohort Study |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.09.2020 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Eribulin is a chemotherapeutic agent used for advanced breast cancer, but there are some reports of eribulin-induced lung injuries. Three of our patients experienced eribulin-related lung injuries. Radiology revealed organizing pneumonia in two cases and diffuse ground-glass shadows indicative of hypersensitivity pneumonitis in the third. A retrospective survey of patients treated with eribulin at our hospital identified no other cases of eribulin-induced lung injuries. Overall, drug-related lung injuries occurred in 2.8% of our eribulin-treated patients, which is similar to the rates reported for other anticancer drugs. The findings from these three cases provide guidance for the safe use of eribulin | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a breast cancer | |
| 650 | 4 | |a eribulin | |
| 650 | 4 | |a interstitial pneumonia | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Furans |2 NLM | |
| 650 | 7 | |a Ketones |2 NLM | |
| 650 | 7 | |a eribulin |2 NLM | |
| 650 | 7 | |a LR24G6354G |2 NLM | |
| 700 | 1 | |a Kanemura, Hiroaki |e verfasserin |4 aut | |
| 700 | 1 | |a Tomishima, Yutaka |e verfasserin |4 aut | |
| 700 | 1 | |a Nakano, Eriko |e verfasserin |4 aut | |
| 700 | 1 | |a Tamura, Tomohide |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Internal medicine (Tokyo, Japan) |d 1996 |g 59(2020), 4 vom: 15. Feb., Seite 563-567 |w (DE-627)NLM012606731 |x 1349-7235 |7 nnns |
| 773 | 1 | 8 | |g volume:59 |g year:2020 |g number:4 |g day:15 |g month:02 |g pages:563-567 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2169/internalmedicine.2779-19 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 59 |j 2020 |e 4 |b 15 |c 02 |h 563-567 | ||